Advertisement
Screener

Siga Technologies INC (SIGA) Net Income (Loss) Attributable to Parent, Diluted

1.6 / 5 stars · 32/98 Roast Me

Siga Technologies INC Net Income (Loss) Attributable to Parent, Diluted

Siga Technologies INC (SIGA) reported Net Income (Loss) Attributable to Parent, Diluted of $59.21 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.

Financial Statements › Income Statement › Net Income

us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2025-03-11

  • Siga Technologies INC net income (loss) attributable to parent, diluted for the quarter ending 2023-12-31 was $72.26M.
  • Siga Technologies INC net income (loss) attributable to parent, diluted for the quarter ending 2023-09-30 was -$393.07K, a 101.19% decline year-over-year.
  • Siga Technologies INC net income (loss) attributable to parent, diluted for the quarter ending 2023-06-30 was -$2.88M, a 244.68% decline year-over-year.
  • Siga Technologies INC net income (loss) attributable to parent, diluted for the quarter ending 2023-03-31 was -$918.25K.
  • Siga Technologies INC net income (loss) attributable to parent, diluted for fiscal 2024 was $59.21M, a 13.01% decline from fiscal 2023.
  • Siga Technologies INC net income (loss) attributable to parent, diluted for fiscal 2023 was $68.07M, a 103.17% increase from fiscal 2022.
  • Siga Technologies INC net income (loss) attributable to parent, diluted for fiscal 2022 was $33.50M, a 51.68% decline from fiscal 2021.
  • Siga Technologies INC net income (loss) attributable to parent, diluted for fiscal 2021 was $69.33M, a 23.06% increase from fiscal 2020.
Period endNet Income (Loss) Attributable to Parent, Diluted 3 monthNet Income (Loss) Attributable to Parent, Diluted 6 monthNet Income (Loss) Attributable to Parent, Diluted 9 monthNet Income (Loss) Attributable to Parent, Diluted 12 monthNet Income (Loss) Attributable to Parent, Diluted 12 month as first filed
2024-12-31$59.21M
10-K · filed 2025-03-11
2023-12-31$72.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
$71.86M
derived: sum of 2 quarters · filed 2025-03-11
$68.99M
derived: sum of 3 quarters · filed 2025-03-11
$68.07M
10-K · filed 2025-03-11
2023-09-30-$393.07K
10-Q · filed 2023-11-07
-$3.27M
derived: sum of 2 quarters · filed 2023-11-07
-$4.19M
10-Q · filed 2023-11-07
-$5.00M
derived: sum of 4 quarters · filed 2025-03-11
2023-06-30-$2.88M
10-Q · filed 2023-08-08
-$3.79M
10-Q · filed 2023-08-08
-$4.61M
derived: sum of 3 quarters · filed 2025-03-11
$28.44M
derived: sum of 4 quarters · filed 2025-03-11
2023-03-31-$918.25K
10-Q · filed 2023-05-04
-$1.73M
derived: sum of 2 quarters · filed 2025-03-11
$31.31M
derived: sum of 3 quarters · filed 2025-03-11
$33.30M
derived: sum of 4 quarters · filed 2025-03-11
2022-12-31-$811.79K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
$32.23M
derived: sum of 2 quarters · filed 2025-03-11
$34.22M
derived: sum of 3 quarters · filed 2025-03-11
$33.50M
10-K · filed 2025-03-11
2022-09-30$33.04M
10-Q · filed 2023-11-07
$35.03M
derived: sum of 2 quarters · filed 2023-11-07
$34.32M
10-Q · filed 2023-11-07
$107.70M
derived: sum of 4 quarters · filed 2024-03-12
2022-06-30$1.99M
10-Q · filed 2023-08-08
$1.28M
10-Q · filed 2023-08-08
$74.66M
derived: sum of 3 quarters · filed 2024-03-12
$71.55M
derived: sum of 4 quarters · filed 2024-03-12
2022-03-31-$712.15K
10-Q · filed 2023-05-04
$72.67M
derived: sum of 2 quarters · filed 2024-03-12
$69.56M
derived: sum of 3 quarters · filed 2024-03-12
$69.30M
derived: sum of 4 quarters · filed 2024-03-12
2021-12-31$73.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
$70.27M
derived: sum of 2 quarters · filed 2024-03-12
$70.01M
derived: sum of 3 quarters · filed 2024-03-12
$69.33M
10-K · filed 2024-03-12
2021-09-30-$3.11M
10-Q · filed 2022-11-03
-$3.37M
derived: sum of 2 quarters · filed 2022-11-03
-$4.05M
10-Q · filed 2022-11-03
$15.06M
derived: sum of 4 quarters · filed 2023-03-02
2021-06-30-$258.93K
10-Q · filed 2022-08-04
-$1.99M
10-Q · filed 2022-08-04
$18.17M
derived: sum of 3 quarters · filed 2023-03-02
$42.36M
derived: sum of 4 quarters · filed 2023-03-02
2021-03-31-$1.73M
10-Q · filed 2022-05-05
$18.43M
derived: sum of 2 quarters · filed 2023-03-02
$42.62M
derived: sum of 3 quarters · filed 2023-03-02
$63.51M
derived: sum of 4 quarters · filed 2023-03-02
2020-12-31$20.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02
$44.35M
derived: sum of 2 quarters · filed 2023-03-02
$65.24M
derived: sum of 3 quarters · filed 2023-03-02
$56.34M
10-K · filed 2023-03-02
2020-09-30$24.19M
10-Q · filed 2021-11-04
$45.08M
derived: sum of 2 quarters · filed 2021-11-04
$36.18M
10-Q · filed 2021-11-04
$31.36M
derived: sum of 4 quarters · filed 2022-03-03
2020-06-30$20.89M
10-Q · filed 2021-08-05
$11.99M
10-Q · filed 2021-08-05
$7.17M
derived: sum of 3 quarters · filed 2022-03-03
$4.99M
derived: sum of 4 quarters · filed 2022-03-03
2020-03-31-$8.90M
10-Q · filed 2021-05-06
-$13.72M
derived: sum of 2 quarters · filed 2022-03-03
-$15.90M
derived: sum of 3 quarters · filed 2022-03-03
-$19.72M
derived: sum of 4 quarters · filed 2022-03-03
2019-12-31-$4.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03
-$7.01M
derived: sum of 2 quarters · filed 2022-03-03
-$10.83M
derived: sum of 3 quarters · filed 2022-03-03
-$12.33M
10-K · filed 2022-03-03
2019-09-30-$2.19M
10-Q · filed 2020-11-05
-$6.01M
derived: sum of 2 quarters · filed 2020-11-05
-$7.51M
10-Q · filed 2020-11-05
$46.53M
derived: sum of 4 quarters · filed 2021-03-04
2019-06-30-$3.82M
10-Q · filed 2020-08-06
-$5.33M
10-Q · filed 2020-08-06
$48.72M
derived: sum of 3 quarters · filed 2021-03-04
$439.10M
derived: sum of 4 quarters · filed 2021-03-04
2019-03-31-$1.51M
10-Q · filed 2020-05-06
$52.54M
derived: sum of 2 quarters · filed 2021-03-04
$442.91M
derived: sum of 3 quarters · filed 2021-03-04
$435.50M
derived: sum of 4 quarters · filed 2021-03-04
2018-12-31$54.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04
$444.42M
derived: sum of 2 quarters · filed 2021-03-04
$437.01M
derived: sum of 3 quarters · filed 2021-03-04
$428.73M
10-K · filed 2021-03-04
$428.73M
10-K · filed 2019-03-06
2018-09-30$390.38M
10-Q · filed 2019-11-05
$382.97M
derived: sum of 2 quarters · filed 2019-11-05
$374.69M
10-Q · filed 2019-11-05
$335.15M
derived: sum of 4 quarters · filed 2019-11-05
2018-06-30-$7.41M
10-Q · filed 2019-08-06
-$18.63M
10-Q · filed 2019-08-06
-$55.23M
derived: sum of 3 quarters · filed 2019-08-06
-$65.05M
derived: sum of 4 quarters · filed 2019-08-06
2018-03-31-$11.58M
10-Q · filed 2019-05-02
-$47.82M
derived: sum of 2 quarters · filed 2019-05-02
-$57.63M
derived: sum of 3 quarters · filed 2019-05-02
2017-12-31-$36.24M
10-K · filed 2019-03-06
-$46.05M
derived: sum of 2 quarters · filed 2019-03-06
-$36.24M
10-K · filed 2020-03-05
2017-09-30-$9.82M
10-Q · filed 2018-11-06
-$25.93M
10-Q · filed 2018-11-06
2016-12-31-$39.70M
10-K · filed 2019-03-06
2013-12-31-$17.18M
10-K · filed 2014-03-10
2012-12-31-$2.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10
-$5.66M
derived: sum of 2 quarters · filed 2014-03-10
-$10.01M
derived: sum of 3 quarters · filed 2014-03-10
-$14.06M
10-K · filed 2014-03-10
-$14.53M
10-K · filed 2013-03-06
2012-09-30-$2.94M
10-Q · filed 2012-11-05
-$7.29M
derived: sum of 2 quarters · filed 2012-11-05
-$11.34M
10-Q · filed 2012-11-05
2012-06-30-$4.35M
10-Q · filed 2012-08-06
-$8.40M
10-Q · filed 2012-08-06
2011-12-31-$6.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10
-$5.95M
derived: sum of 2 quarters · filed 2014-03-10
$15.85M
derived: sum of 3 quarters · filed 2014-03-10
$4.66M
10-K · filed 2014-03-10
2011-09-30$210.51K
10-Q · filed 2012-11-05
$22.01M
derived: sum of 2 quarters · filed 2012-11-05
$10.82M
10-Q · filed 2012-11-05
2011-06-30$21.80M
10-Q · filed 2012-08-06
$15.34M
10-Q · filed 2012-08-06
2010-12-31-$50.35M
10-K/A · filed 2013-05-15
-$28.20M
10-K · filed 2013-03-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B